"Thiophenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Below are MeSH descriptors whose meaning is more general than "Thiophenes".
Below are MeSH descriptors whose meaning is more specific than "Thiophenes".
This graph shows the total number of publications written about "Thiophenes" by people in this website by year, and whether "Thiophenes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Thiophenes" by people in Profiles.
Allosteric inhibitors of Mycobacterium tuberculosis tryptophan synthase. Protein Sci. 2020 03; 29(3):779-788.
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. Eur J Med Chem. 2017 Dec 01; 141:149-161.
Inhibition of 12/15-Lipoxygenase Protects Against ?-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 11; 66(11):2875-2887.
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52.
T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6110-6117.
S1P1 deletion in oligodendroglial lineage cells: Effect on differentiation and myelination. Glia. 2016 Apr; 64(4):570-82.
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol. 2015 Feb; 110(2):328-35.